PREVALENCE OF DRUG RESISTANCE TO FIRST LINE DRUGS AMONG TUBERCULOSIS PATIENTS IN ASTANA ; РАСПРОСТРАНЕНИЕ ВОЗБУДИТЕЛЯ С УСТОЙЧИВОСТЬЮ К ПРЕПАРАТАМ ПЕРВОГО РЯДА СРЕДИ БОЛЬНЫХ ТУБЕРКУЛЕЗОМ В Г. АСТАНЕ

Συγγραφείς: Z. K. Rakisheva, G. S. Balasanyants, A. S. Akisheva, A. B. Tsepke, N. S. Solovieva, Ж. К. Ракишева, Г. С. Баласанянц, А. С. Акишева, А. Б. Цепке, Н. С. Соловьева

Πηγή: Tuberculosis and Lung Diseases; Том 96, № 8 (2018); 50-54 ; Туберкулез и болезни легких; Том 96, № 8 (2018); 50-54 ; 2542-1506 ; 2075-1230

Θεματικοί όροι: противотуберкулезные препараты первого ряда, multiple resistance, polyresistance, first line anti-tuberculosis drugs, мультирезистентность, полирезистентность

Περιγραφή αρχείου: application/pdf

Relation: https://www.tibl-journal.com/jour/article/view/1165/1167; Al-Mutairi N. M., Ahmad S., Mokaddas E. Molecular screening versus phenotypic susceptibility testing of multidrug-resistant mycobacterium tuberculosis Isolates for streptomycin and ethambutol // Microb. Drug. Resist. – 2018. – Jan. 16. https://doi.org/10.1089/mdr.2017.0294; Asaad A. M., Alqahtani J. M. Primary anti-tuberculous drugs resistance of pulmonary tuberculosis in southwestern Saudi Arabia // J. Infect. Public Health. – 2012. – Vol. 5, № 4. – P. 281-285.; Cambau E., Viveiros M., Machado D., Raskine L., Ritter C., Tortoli E., Matthys V., Hoffner S., Richter E., Del Molino M. P., Cirillo D. M. Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study // J. Antimicrob. Chemother. – 2015. – Vol. 70, № 3. – P. 686-696.; Kim H. W., Kim J. S. Treatment of latent tuberculosis infection and its clinical efficacy // Tuberc. Respir. Dis. (Seoul). – 2018. – Vol. 81, № 1. – Р. 6-12.; Kuo C. Y., Wang W. H., Huang C. H., Chen Y. H., Lu P. L. Resistance to first- and second-line antituberculosis drugs in Southern Taiwan: Implications for empirical treatment // J. Microbiol. Immunol. Infect. – 2017. – Vol. 17. – Р. S1684-S1182.; Meyssonnier V., van Bu Th., Veziris N. et al. Rifampicin mono-resistant tuberculosis in France: a 2005-2010 retrospective cohort analysis // DVC Infect. Dis. – 2014. – Vol. 14. – Р. 18.; Migliori G. B., Zellweger J. P., Abubakar I. et al. European Union standards for tuberculosis care // Eur Respir J. – 2012. – Vol. 39, № 4. – Р. 807-819.; National Institute for Health and Clinical Excellence (NICE) Tuberculosis (NICE guideline 33) // London: NICE, 2016; The end TB strategy: global strategy and targets for tuberculosis prevention, care and control after 2015 // Geneva, World Health Organization, 2014.; World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis.5th ed. // Geneva: WHO, 2015.; World Health Organization. Treatment guidelines for drug-resistant tuberculosis // Geneva: WHO, 2016.; World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update // Geneva: WHO, 2011.; Zignol M., Dean A. S., Alikhanova N. et al. Population-based resistance of mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project // Lancet Infect. Dis. – 2016. – Vol. 16, № 10. – Р. 1185-1192.

Διαθεσιμότητα: https://www.tibl-journal.com/jour/article/view/1165
https://doi.org/10.21292/2075-1230-2018-96-8-50-54

PREVALENCE OF DRUG RESISTANCE TO FIRST LINE DRUGS AMONG TUBERCULOSIS PATIENTS IN ASTANA

Συγγραφείς: Z. K. Rakisheva, G. S. Balasanyants, A. S. Akisheva, A. B. Tsepke, N. S. Solovieva

Πηγή: Туберкулез и болезни лёгких, Vol 96, Iss 8, Pp 50-54 (2018)

Θεματικοί όροι: туберкулез, мультирезистентность, полирезистентность, противотуберкулезные препараты первого ряда, Diseases of the respiratory system, RC705-779

Relation: https://www.tibl-journal.com/jour/article/view/1165; https://doaj.org/toc/2075-1230; https://doaj.org/toc/2542-1506; https://doaj.org/article/daf1cb729f0e449d857598cd775a02a2

Διαθεσιμότητα: https://doi.org/10.21292/2075-1230-2018-96-8-50-54
https://doaj.org/article/daf1cb729f0e449d857598cd775a02a2